-
Something wrong with this record ?
Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide
B. Wawrzycki, G. Chodorowska, A. Pietrzak, I. Jazienicka, D. Skomra, M. Kowal, E. Dybiec, J. Hercogova
Language English Country Denmark
Document type Case Reports, Journal Article
NLK
Medline Complete (EBSCOhost)
from 2000-01-01
Wiley Online Library (archiv)
from 2000-01-01 to 2012-12-31
- MeSH
- Antineoplastic Agents, Alkylating therapeutic use MeSH
- Biopsy MeSH
- CD4-Positive T-Lymphocytes drug effects immunology pathology MeSH
- Leukemia, Myelomonocytic, Chronic drug therapy immunology pathology MeSH
- Cyclophosphamide therapeutic use MeSH
- Immunohistochemistry MeSH
- Lymphoma, T-Cell, Cutaneous complications drug therapy immunology pathology MeSH
- Skin immunology pathology MeSH
- Humans MeSH
- Myelodysplastic Syndromes drug therapy immunology pathology MeSH
- Skin Neoplasms drug therapy immunology pathology MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy. We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.
Chair and Department of Hematooncology and Bone Marrow Transplantation Medical University of Lublin
Department of Clinical Pathomorphology Medical University of Lublin
Department of Dermatology 2nd Medical Faculty Charles University Prague Czech Republic
Department of Pediatric Radiology Medical University of Lublin
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026674
- 003
- CZ-PrNML
- 005
- 20160307112123.0
- 007
- ta
- 008
- 120816s2010 dk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1529-8019.2010.01372.x $2 doi
- 035 __
- $a (PubMed)21054711
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a dk
- 100 1_
- $a Wawrzycki, Bartłomiej $u Chair and Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin, Prague, Czech Republic. bartekwawrzycki@o2.pl
- 245 10
- $a Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide / $c B. Wawrzycki, G. Chodorowska, A. Pietrzak, I. Jazienicka, D. Skomra, M. Kowal, E. Dybiec, J. Hercogova
- 520 9_
- $a Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy. We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a alkylační protinádorové látky $x terapeutické užití $7 D018906
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x účinky léků $x imunologie $x patologie $7 D015496
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a chronická myelomonocytární leukemie $x farmakoterapie $x imunologie $x patologie $7 D015477
- 650 _2
- $a kožní T-buněčný lymfom $x komplikace $x farmakoterapie $x imunologie $x patologie $7 D016410
- 650 _2
- $a myelodysplastické syndromy $x farmakoterapie $x imunologie $x patologie $7 D009190
- 650 _2
- $a kůže $x imunologie $x patologie $7 D012867
- 650 _2
- $a nádory kůže $x farmakoterapie $x imunologie $x patologie $7 D012878
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chodorowska, Grazyna $u Chair and Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin
- 700 1_
- $a Pietrzak, Aldona $u Chair and Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin
- 700 1_
- $a Jazienicka, Iwona $u Chair and Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin
- 700 1_
- $a Skomra, Danuta $u Department of Clinical Pathomorphology Medical University of Lublin
- 700 1_
- $a Kowal, Małgorzata $u Chair and Department of Hematooncology and Bone Marrow Transplantation Medical University of Lublin
- 700 1_
- $a Dybiec, Ewa $u Department of Pediatric Radiology, Medical University of Lublin
- 700 1_
- $a Třešňák Hercogová, Jana, $d 1959- $7 nlk19990073221 $u Department of Dermatology, Second Medical Faculty, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00005384 $t Dermatologic therapy $x 1529-8019 $g Roč. 23, č. 6 (2010), s. 676-681
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21054711 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160307112139 $b ABA008
- 999 __
- $a ok $b bmc $g 948716 $s 784020
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 23 $c 6 $d 676-681 $i 1529-8019 $m Dermatologic therapy $n Dermatol Ther $x MED00005384
- LZP __
- $b NLK122 $a Pubmed-20120816/11/01